Patent classifications
C07D211/54
CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS
A composition-of-matter comprising a crystallized form of a large ribosomal (50S) subunit of a pathogenic bacterium, and the atomic coordinates of the three-dimensional structure thereof are provided herein, as well as methods for crystallizing the same, and using the atomic coordinates of the same to design de novo ligands with high specificity thereto.
CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS
A composition-of-matter comprising a crystallized form of a large ribosomal (50S) subunit of a pathogenic bacterium, and the atomic coordinates of the three-dimensional structure thereof are provided herein, as well as methods for crystallizing the same, and using the atomic coordinates of the same to design de novo ligands with high specificity thereto.
N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
##STR00001##
N-ACYL-{4-[(4-ARYL-PHENYL)SULFONYLMETHYL]PIPERIDINE} COMPOUNDS AND THEIR THERAPEUTIC USE
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain N-acyl-{4-[(4-aryl-phenyl)sulfonylmethyl]piperidine} compounds of the following formula (collectively referred to herein as NASMP compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, e.g., multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, eosinophilic leukemia, glioblastoma, melanoma, ovarian cancer, chemotherapy resistant cancer, radiation resistant cancer, inflammatory arthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease, systemic lupus erythematosus (SLE), lupus nephritis, asthma, chronic obstructive pulmonary disease (COPD), Hidradenitis suppurativa, autoimmune hepatitis, etc. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
##STR00001##
1,4-substituted piperidine derivatives
Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##
1,4-substituted piperidine derivatives
Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. ##STR00001##
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
Provided are a family of chromophores including naphthyl or naphthyl-like carbocyclic or heterocyclic rings as luminescent dyes that can be useful as emitters in OLEDs. These compounds have Formula I,
##STR00001##
Also provided are formulations including these inventive compounds. Further provided are OLEDs and related consumer products that utilize these inventive compounds.
ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
Provided are a family of chromophores including naphthyl or naphthyl-like carbocyclic or heterocyclic rings as luminescent dyes that can be useful as emitters in OLEDs. These compounds have Formula I,
##STR00001##
Also provided are formulations including these inventive compounds. Further provided are OLEDs and related consumer products that utilize these inventive compounds.
Hydrolytically labile heterocycles of odoriferous ketones or odoriferous aldehydes
Heterocycles having odoriferous ketone or odoriferous aldehyde groups may be suitable in compositions comprising washing agents, cleaning agents, cosmetic agents, air care agents, insect repellents, or combinations thereof where the heterocycles release the ketones and aldehydes during hydrolysis. The heterocycle(s) may have the formula: ##STR00001##
Hydrolytically labile heterocycles of odoriferous ketones or odoriferous aldehydes
Heterocycles having odoriferous ketone or odoriferous aldehyde groups may be suitable in compositions comprising washing agents, cleaning agents, cosmetic agents, air care agents, insect repellents, or combinations thereof where the heterocycles release the ketones and aldehydes during hydrolysis. The heterocycle(s) may have the formula: ##STR00001##